Lixisenatide began as ZP10A, a peptide designed at Zealand Pharma in Denmark and described in 2003. Sanofi developed it under the code AVE0010. FDA approved Adlyxin on July 27, 2016, and Soliqua 100/33 on November 21, 2016. Because the peptide is longer than 40 amino acids, FDA has regulated both products as biologics since March 23, 2020.
Quick answer: Lixisenatide is a GLP-1 receptor agonist peptide. Lixisenatide is FDA-approved as Adlyxin and as one of the two active ingredients in Soliqua 100/33. The European Commission withdrew the stand-alone product, Lyxumia, in December 2025 for commercial reasons. Approval covers labeled products, not research material sold under the same name.
Vitrapep does not sell lixisenatide; this page is a reference summary of published research and regulatory information.
What is lixisenatide and where did it come from?
Lixisenatide starts from exendin-4, a 39-amino-acid peptide isolated from Gila monster venom in 1992 (Eng et al., 1992). Exendin-4 is also the basis of exenatide, covered in Vitrapep's exenatide complete guide. PubChem records lixisenatide as exendin-4 (1-39) without proline 38, followed by six lysines and an amidated end [3].
In 2003, Zealand Pharma scientists described the designed peptide as ZP10A. In binding studies, its affinity for the human GLP-1 receptor was 4-fold greater than that of GLP-1 (7-36) amide. In diabetic db/db mice, 42 days of treatment lowered HbA1c. These were cell and animal findings [5].
FDA's 2016 review says the six lysines were added to block breakdown by the enzyme dipeptidyl peptidase-4 and to lengthen the peptide's time in circulation. The drug substance is made by chemical synthesis [4].
What is lixisenatide and where did it come from
| Property | Lixisenatide |
|---|---|
| Class | GLP-1 receptor agonist; the label calls it a synthetic analogue of human GLP-1 [1] |
| Sequence | HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2 [3] |
| Design | Exendin-4 (1-39) without proline 38, plus six lysines; amidated at position 44 [1], [3] |
| Molecular formula | C215H347N61O65S (PubChem CID 90472060) [3] |
| Molecular weight | 4858 g/mol in PubChem; 4.8585 kDa on the label [1], [3] |
| Development codes | ZP10A (Zealand Pharma) and AVE0010 (Sanofi) [3], [5] |
| Mean terminal half-life | About 3 hours; presumed elimination by glomerular filtration and proteolytic breakdown [1] |
| US approvals | Adlyxin, July 27, 2016; Soliqua 100/33, November 21, 2016 (Drugs@FDA) |
| US regulatory category | Former new drug applications deemed biologics licenses on March 23, 2020 [12] |
| EU status | Lyxumia authorized 2013 and withdrawn December 18, 2025; Suliqua authorized January 11, 2017 (EMA) |
| Boxed warning | None on the Adlyxin or Soliqua 100/33 labels [1], [2] |
How does lixisenatide work?
Lixisenatide activates the GLP-1 receptor, whose signaling is explained in Vitrapep's guide to how GLP-1 receptor agonists work. The label states that it increases glucose-dependent insulin release, lowers glucagon secretion and slows gastric emptying [1].
Its effect falls mostly on blood sugar after meals. In a label pharmacology study, the post-meal glucose effect was largest with the first meal and weaker with later meals [1].
Slower stomach emptying appears to drive much of this. In a 28-day placebo-controlled study of 43 adults with type 2 diabetes, lixisenatide substantially lengthened gastric emptying time. Slower emptying tracked with lower glucose after breakfast (Lorenz et al., 2013).
A randomized 8-week trial compared lixisenatide with liraglutide in 142 adults on optimized insulin glargine. Lixisenatide lowered post-breakfast glucose more and delayed gastric emptying more. Liraglutide raised 24-hour heart rate by 9 beats per minute, versus 3 with lixisenatide. Symptomatic hypoglycemia was more frequent with lixisenatide, and gastrointestinal events with liraglutide [6].
What is lixisenatide approved for?
Approved uses come from section 1 of each label; other approved peptides appear in Vitrapep's list of FDA-approved peptide medicines.
Adlyxin is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Safety and effectiveness have not been established in pediatric patients [1].
Soliqua 100/33 adds insulin glargine, a basal insulin analog, and carries the same adult indication. Its limitations of use advise against combining it with other GLP-1 receptor agonist products. It has not been studied with mealtime insulin [2].
Neither label lists cardiovascular risk reduction or weight management in section 1 [1], [2]. The liraglutide complete guide covers a related medicine whose label does include a cardiovascular indication.
What did the key lixisenatide trials show?
GetGoal-X (NCT00707031) compared lixisenatide with immediate-release exenatide in 634 adults on metformin for 24 weeks. Lixisenatide met its noninferiority margin, but the label notes a statistically smaller HbA1c drop [1], [7]. Nausea occurred in 24.5% versus 35.1%, and symptomatic hypoglycemia in 2.5% versus 7.9% [7].
ELIXA (NCT01147250) enrolled 6,068 adults with type 2 diabetes and a heart attack or unstable angina hospitalization within 180 days. Heart failure hospitalization and death did not differ significantly [8].
LixiLan-O (NCT02058147) and LixiLan-L (NCT02058160) tested Soliqua against one or both of its components. In LixiLan-O, HbA1c below 7% was reached by 74% on Soliqua, 59% on insulin glargine and 33% on lixisenatide [9]. In LixiLan-L, mean weight fell 0.7 kg on Soliqua and rose 0.7 kg on insulin glargine [10].
What did the key lixisenatide trials show
| Trial | Population and size | Design and length | Primary result |
|---|---|---|---|
| GetGoal-X, 2013 [7] | 634 adults with type 2 diabetes on metformin | Randomized, open-label, versus exenatide; 24 weeks | HbA1c fell 0.79 vs 0.96 points; difference 0.17 (95% CI, 0.033 to 0.297), within the noninferiority margin |
| ELIXA, 2015 [8] | 6,068 adults with type 2 diabetes and a recent acute coronary syndrome | Double-blind, placebo-controlled; median 25 months | Major cardiovascular events 13.4% vs 13.2%; hazard ratio 1.02 (95% CI, 0.89 to 1.17); noninferior, not superior |
| LixiLan-O, 2016 [9] | 1,170 adults with type 2 diabetes on metformin | Randomized, open-label, three arms; 30 weeks | HbA1c fell 1.6 (Soliqua), 1.3 (insulin glargine) and 0.9 points (lixisenatide) |
| LixiLan-L, 2016 [10] | 736 adults with type 2 diabetes on basal insulin | Randomized, open-label, two arms; 30 weeks | HbA1c fell 1.1 (Soliqua) vs 0.6 points (insulin glargine); P < 0.0001 |
All four are human randomized trials sponsored by Sanofi. Vitrapep's guide on how to find a peptide clinical trial explains how to read these registry records.
What else has lixisenatide been studied for?
Protective effects in a mouse model of Parkinson's disease, an animal finding, led to a human trial [11].
LIXIPARK (NCT03439943) was a phase 2, double-blind, placebo-controlled trial in France. It enrolled 156 people diagnosed with Parkinson's disease less than 3 years earlier. Treatment lasted 12 months, followed by a 2-month washout.
At 12 months, motor scores changed by -0.04 points on lixisenatide and worsened by 3.04 points on placebo. The difference was 3.08 points (95% CI, 0.86 to 5.30). Nausea affected 46% on lixisenatide and vomiting 13% [11].
The authors called for longer and larger trials [11]. On November 18, 2026, ClinicalTrials.gov showed no posted results and no other Parkinson's trial of lixisenatide. Several active studies, such as NCT06671587 in China, test the insulin combination in diabetes.
What side effects do the lixisenatide labels list?
No boxed warning. Neither the Adlyxin nor the Soliqua label carries one [1], [2]. FDA's review ties the theoretical thyroid C-cell tumor risk to longer-acting GLP-1 receptor agonists [4]. Rats still developed more thyroid C-cell adenomas at all lixisenatide doses tested [1]. FDA judged this tumor profile closer to that of short-acting agonists [4].
What side effects do the lixisenatide labels list
| Adverse reaction | Adlyxin, % (N=2869) | Placebo, % (N=1639) |
|---|---|---|
| Nausea | 25 | 6 |
| Vomiting | 10 | 2 |
| Headache | 9 | 6 |
| Diarrhea | 8 | 6 |
| Dizziness | 7 | 4 |
Source: Adlyxin label, Table 1, pooled placebo-controlled trials with a mean exposure of 21.7 weeks [1]. Gastrointestinal reactions occurred in 39.7% versus 18.4%. Most began in the first 3 weeks, and 4.3% versus 0.5% stopped treatment because of them [1].
Hypoglycemia. Risk rises with insulin or a sulfonylurea. With both, 47.2% on Adlyxin reported symptomatic hypoglycemia versus 21.6% on placebo [1]. For Soliqua, hypoglycemia is the most common adverse reaction, and nausea occurred in 10.0% [2].
Allergy and antibodies. Adjudicated anaphylaxis occurred at 16 versus 7 cases per 10,000 patient-years on placebo [1]. In pooled studies, 70% of patients developed anti-lixisenatide antibodies. The 2.4% with the highest levels had a weaker glucose response. Antibody-positive patients had more allergic and injection-site reactions [1]. Some antibodies may cross-react with natural GLP-1 and glucagon, with unknown clinical significance [1]. FDA required a postmarketing antibody study at approval (approval letter).
Other warnings. Pancreatitis occurred at 21 versus 17 cases per 10,000 patient-years on comparators. The label also warns of acute kidney injury from dehydration, severe gastrointestinal reactions, gallbladder disease and pulmonary aspiration during anesthesia [1]. Soliqua adds insulin warnings, including hypokalemia [2].
Eye warning. On November 9, 2026, FDA required all GLP-1 receptor agonist labels to warn of a possible increased risk of NAION, a rare optic nerve condition. Pooled data from 126 trials showed 6.4 cases per 100,000 person-years versus 3.8 with comparators [14]. FDA's product table lists Soliqua but not Adlyxin [14]. The Soliqua label on DailyMed did not yet show the warning on November 18, 2026. See Vitrapep's summary of FDA's GLP-1 eye-risk warning.
What is the regulatory status of lixisenatide?
Approval history. FDA's review notes that an earlier application, NDA 204961, was withdrawn. At a May 25, 2016, FDA advisory committee meeting, members noted concern about anti-drug antibodies and rare severe allergic reactions. The concern was not enough to oppose marketing [4].
Why it became a biologic. A 2020 FDA rule defines a protein as an amino acid polymer greater than 40 amino acids in size (Federal Register). Lixisenatide has 44. On March 23, 2020, the Adlyxin and Soliqua applications were deemed biologics licenses [12]. Exenatide, at 39 amino acids, falls below that line.
Compounding. FDA states that licensed biological products are not eligible for the compounding exemptions in sections 503A and 503B. Since March 23, 2020, that group includes Adlyxin and Soliqua [12], [13].
US market presence. Drugs@FDA still lists Adlyxin with a prescription marketing status. On November 18, 2026, however, DailyMed and FDA's NDC Directory listed only Soliqua 100/33 (DailyMed). FDA's own databases therefore disagree on whether Adlyxin is marketed.
Europe. Lyxumia was authorized in the EU on February 1, 2013. The European Commission withdrew it on December 18, 2025, at Sanofi's request, for commercial reasons (EMA). Suliqua, the insulin glargine combination, has been authorized since January 11, 2017 (EMA).
Sport. The WADA 2026 Prohibited List does not name lixisenatide or GLP-1 receptor agonists. It does prohibit insulins at all times under S4.4.2, and Soliqua contains insulin glargine.
Research-labeled products. A research-use-only label does not make a product approved, legal or safe for people. See research peptides and human-use risks and why research peptides have no dose.
What is still unknown about lixisenatide?
In ELIXA, FDA reviewers saw numerical imbalances in thyroid, colorectal and prostate cancers, each from 3 to 6 excess cases on lixisenatide. They judged these likely due to chance [4]. FDA found no animal mechanism that would explain NAION [14]. In Parkinson's disease, only one 12-month phase 2 trial has reported results [11].
Frequently asked questions
Is lixisenatide a peptide?
Yes. It is a synthetic chain of 44 amino acids. Because it exceeds 40 amino acids, FDA treats it as a protein and regulates its products as biologics.
What is Soliqua 100/33?
It is a single product containing insulin glargine and lixisenatide. FDA approved it in November 2016 to improve glycemic control in adults with type 2 diabetes.
Is Adlyxin still sold in the US?
FDA records conflict. Drugs@FDA lists Adlyxin as an approved prescription product, but DailyMed and the NDC Directory showed no Adlyxin listing on November 18, 2026.
Did lixisenatide reduce heart attacks or strokes in ELIXA?
No. Major cardiovascular events occurred in 13.4% on lixisenatide versus 13.2% on placebo. The trial showed noninferiority, not superiority.
Has lixisenatide been tested in Parkinson's disease?
Yes. The 156-person phase 2 LIXIPARK trial reported less motor decline than placebo at 12 months. Nausea affected 46% of participants on lixisenatide.
Is research-grade lixisenatide FDA-approved?
No. FDA approval covers Adlyxin and Soliqua 100/33 made under approved applications. Material sold for laboratory research is not an approved medicine.
What to know now
- Lixisenatide is a 44-amino-acid exendin-4 analog, approved in the US in 2016 as Adlyxin and as part of Soliqua 100/33.
- ELIXA showed cardiovascular noninferiority to placebo, not superiority; neither US label carries a boxed warning.
- The EU withdrew Lyxumia in December 2025; the insulin combination stays authorized in the US and EU, while FDA records conflict on Adlyxin.
What we’re watching
- NAION warning text appearing on lixisenatide labels after FDA's November 2026 requirement.
- Whether a larger, longer Parkinson's disease trial follows LIXIPARK.
- Whether FDA's databases come to agree on Adlyxin's US marketing status.